Literature DB >> 10430330

Immunoglobulins and IgG subclasses in patients with inflammatory bowel disease.

I Gouni-Berthold1, B Baumeister, H K Berthold, C Schmidt.   

Abstract

BACKGROUND/AIMS: Serum immunoglobulin levels and distribution are altered in patients with inflammatory bowel disease (IBD). The purpose of this study is to examine the value of serum concentration of IgG subclasses for the diagnosis and evaluation of disease activity of IBD and to assess possible differences in the immunoglobulin changes between patients with Crohn's disease (CD) and ulcerative colitis (UC).
METHODOLOGY: We measured serum IgG and IgG subclasses concentrations as well as IgA, IgM, ESR, CRP, elastase levels and granulocyte count of 96 patients with chronic IBD (69 with CD and 27 with UC) with various levels of disease activity.
RESULTS: The total IgG levels in patients with UC were significantly increased, for both active and inactive disease, compared to those of patients with CD. The IgG1 concentration in patients with UC (7+/-0.77 mg/ml) was significantly higher than in patients with CD (5.6+/-0.61 mg/ml) (p<0.02). The IgG2 levels in CD were significantly higher than those of UC (4.6+/-0.64 vs. 3.8+/-0.57 mg/ml) (p<0.05). The IgG4 levels of UC patients were significantly higher than those of the CD patients (0.39+/-0.06 vs. 0.29+/-0.05 mg/ml) (p<0.05). No significant differences were found in the serum concentrations of IgG3, IgA and IgM between the two groups. There was a negative correlation between the various indices of disease activity and the concentration of IgG3 in patients with UC (p<0.01), and a positive correlation in patients with CD for IgG1 (p<0.001), IgG2 (p<0.001) and IgA (p<0.01).
CONCLUSIONS: In IBD some of the IgG immunoglobulin subclass concentration changes correlate, positively or negatively, with disease activity and therefore could be used as additional markers of it. However, serum immunoglobulin levels cannot be used to differentiate between UC and CD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430330

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  10 in total

1.  IgA autoreactivity: a feature common to inflammatory bowel and connective tissue diseases.

Authors:  L Kazemi-Shirazi; C H Gasche; S Natter; A Gangl; J Smolen; S Spitzauer; P Valent; D Kraft; R Valenta
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

2.  Role of perioperative parenteral nutrition in severely malnourished patients with Crohn's disease.

Authors:  Guo-Xiang Yao; Xiu-Rong Wang; Zhu-Ming Jiang; Si-Yuang Zhang; An-Ping Ni
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

3.  Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells.

Authors:  Michael E Burczynski; Ron L Peterson; Natalie C Twine; Krystyna A Zuberek; Brendan J Brodeur; Lori Casciotti; Vasu Maganti; Padma S Reddy; Andrew Strahs; Fred Immermann; Walter Spinelli; Ulrich Schwertschlag; Anna M Slager; Monette M Cotreau; Andrew J Dorner
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

4.  Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines.

Authors:  Iris Dotan; Lael Werner; Sharon Vigodman; Shradha Agarwal; Jorge Pfeffer; Noya Horowitz; Lisa Malter; Maria Abreu; Thomas Ullman; Hanan Guzner-Gur; Zamir Halpern; Lloyd Mayer
Journal:  Inflamm Bowel Dis       Date:  2011-03-15       Impact factor: 5.325

5.  Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.

Authors:  E Furrie; S Macfarlane; J H Cummings; G T Macfarlane
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

6.  Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.

Authors:  Nicholas Horton; Xianrui Wu; Jessica Philpott; Ari Garber; Jean-Paul Achkar; Aaron Brzezinski; Bret A Lashner; Bo Shen
Journal:  Dig Dis Sci       Date:  2016-09-12       Impact factor: 3.199

7.  Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease.

Authors:  Tarun Rai; Xianrui Wu; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-01-30

8.  Adaptive Returns of Deficient Systemic Plasma Immunoglobulin G Levels as Rehabilitation Biomarker After Emergency Colectomy for Fulminant Ulcerative Colitis.

Authors:  Alexander T Hawkins; Jun W Um; Amosy E M'Koma
Journal:  Clin Med Insights Gastroenterol       Date:  2017-12-13

9.  Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy.

Authors:  María José García; Juan Carlos Rodríguez-Duque; Marta Pascual; Coral Rivas; Beatriz Castro; Sandra Raso; Marcos López-Hoyos; María Teresa Arias-Loste; Montserrat Rivero
Journal:  Therap Adv Gastroenterol       Date:  2022-03-02       Impact factor: 4.409

10.  Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease.

Authors:  Tim Hendrikx; Martin L Watzenböck; Sofie M A Walenbergh; Shahzada Amir; Sabrina Gruber; Maria Ozsvar Kozma; Heike I Grabsch; Ger H Koek; Marieke J Pierik; Katharina Staufer; Michael Trauner; Satish C Kalhan; Daisy Jonkers; Marten H Hofker; Christoph J Binder; Ronit Shiri-Sverdlov
Journal:  BMC Med       Date:  2016-07-22       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.